Royal Marsden Hospital
Head of radioisotope physics
Dr Glenn Flux is Head of Radioisotope Physics at the Royal Marsden Hospital and Institute of Cancer Research in Sutton, UK. His main research focus is on translational quantitative SPECT and PET imaging and its application to internal dosimetry for molecular radiotherapy. He has been involved in the development of imaging and dosimetry for clinical procedures including I-131 mIBG treatment of neuroblastoma and the treatment and palliation of bone metastases from prostate cancer with Re-186 HEDP and Ra-223. He has published over 100 peer reviewed articles and received research funding from national and international bodies. He is a founder member of the EANM Dosimetry Committee and is currently chair of the British Nuclear Medicine Society Molecular Radiotherapy committee.
The emergence and resurgence of radiotherapeutics for cancer treatment
Cancer treatment with radiopharmaceuticals is growing rapidly with many new radiotherapeutics either in development or early phase trials. Molecular radiotherapy and theragnostics promise to offer significant advances in cancer care and the market is expected to grow by 30% per annum for the foreseeable future. This presentation will review the potential impact of this expansion for industry, academia, and patient benefit.
EVEN MORE SEMINARS
Professor David Maintz University Hospital Cologne, Department of Radiology
Spectral CT: Dual layer technology helps to increase diagnostic confidence
Dr John Buscombe British Nuclear Medicine Society
Theranostics in prostate cancer new or false dawn
Dr Jagrit Shah Vice President of the British Society of Head & Neck Imaging
Chairing Session 3. Upper Aerodigestive Tract
Sanjay Prabhu, MBBS Harvard Medical School / Boston Children’s Hospital
3D printing, virtual surgery and mixed reality in the OR - fad or trend?
Professor Sanjay Gandhi North Bristol NHS Trust
Role of CAD and AI in lung and colorectal cancers